Molnupiravir for SARS-CoV-2 infection: Public health and policy implications
Open Access
- 23 December 2022
- journal article
- review article
- Published by Elsevier in Journal of Infection
- Vol. 86 (2) , 121-122
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive TrialSSRN Electronic Journal, 2022
- COVID-19 vaccine effectiveness against the omicron (BA.2) variant in EnglandThe Lancet Infectious Diseases, 2022
- Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort studyThe Lancet, 2022
- Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized PatientsNew England Journal of Medicine, 2021